[Long-term theophylline therapy of bronchial asthma].

M. Merlini,G. La Medica,G. Zappa,B. Fregonese,A. Borzone,I. Macciò,G. Vallarino

1983-03-31

Minerva Pediatrica

Abstract:

What problem does this paper attempt to address?

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Oliver Distler,Shervin Assassi,Vincent Cottin,Maurizio Cutolo,Sonye K Danoff,Christopher P Denton,Jörg H W Distler,Anna-Maria Hoffmann-Vold,Sindhu R Johnson,Ulf Müller Ladner,Vanessa Smith,Elizabeth R Volkmann,Toby M Maher

DOI: https://doi.org/10.1183/13993003.02026-2019

2020-05-14

Abstract:Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5-9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1-2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease

Anna-Maria Hoffmann-Vold,Yannick Allanore,Elisabeth Bendstrup,Cosimo Bruni,Oliver Distler,Toby M Maher,Marlies Wijsenbeek,Michael Kreuter

DOI: https://doi.org/10.1186/s12931-020-01459-0

2020-07-23

Abstract:Systemic sclerosis (SSc) is a multi-organ autoimmune disease with complex interactions between immune-mediated inflammatory processes and vascular pathology leading to small vessel obliteration, promoting uncontrolled fibrosis of skin and internal organs. Interstitial lung disease (ILD) is a common but highly variable manifestation of SSc and is associated with high morbidity and mortality. Treatment approaches have focused on immunosuppressive therapies, which have shown some efficacy on lung function. Recently, a large phase 3 trial showed that treatment with nintedanib was associated with a reduction in lung function decline. None of the conducted randomized clinical trials have so far shown convincing efficacy on other outcome measures including quality of life determined by patient reported outcomes. Little evidence is available for non-pharmacological treatment and supportive care specifically for SSc-ILD patients, including pulmonary rehabilitation, supplemental oxygen, symptom relief and adequate information. Improved management of SSc-ILD patients based on a holistic approach is necessary to support patients in maintaining as much quality of life as possible throughout the disease course and to improve long-term outcomes.
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Anna-Maria Hoffmann-Vold,Yannick Allanore,Margarida Alves,Cathrine Brunborg,Paolo Airó,Lidia P Ananieva,László Czirják,Serena Guiducci,Eric Hachulla,Mengtao Li,Carina Mihai,Gabriela Riemekasten,Petros P Sfikakis,Otylia Kowal-Bielecka,Antonella Riccardi,Oliver Distler,Marco Matucci Cerinic,Ulrich Walker,Florenzo Iannone,Radim Becvar,Gabriele Valentini,Elise Siegert,C. Montecucco,Patricia E. Carreira,Carlo Chizzolini,Eugene J. Kucharz,Andrea Doria,Pr Dominique Farge Bancel,Roger Hesselstrand,Alexandra Balbir-Gurman,Raffaele Pellerito,Cristian Caimmi,Christopher Denton,Nemanja Damjanov,Jörg Henes,Vera Ortiz-Santamaria; Stefan Heitmann,Maria João Salvador,Bojana Stamenkovic,Carlo Francesco Selmi,Ariane Herrick,Ulf Müller-Ladner,Merete Engelhart,Valeria Riccieri,Ruxandra Maria Ionescu,Ana Maria Gheorghiu,Cord Sunderkötter,Jörg Distler,Francesca Ingegnoli,Luc Mouthon,Vanessa Smith,Francesco Paolo Cantatore,Susanne Ullman,Maria Rosa Pozzi,Piotr Wiland,Marie Vanthuyne,Brigitte Krummel-Lorenz,Petra Saar,Kristine Herrmann,Ellen De Langhe,Branimir Anic,Marko Baresic,Miroslav Mayer,Sule Yavuz,Carolina de Souza Müller,Thierry Zenone,Alessandro Mathieu,Alessandra Vacca,Kamal Solanki,Edoardo Rosato,Fahrettin Oksel,Figen Yargucu,Cristina-Mihaela Tanaseanu,Rosario Foti,Daniel E. Furst,Peter Villiger,Sabine Adler,Paloma García de la Peña Lefebvre,Jorge Juan González Martín,Ira Litinsky,Francesco Del Galdo,Goda Seskute,Lesley Ann Saketkoo,Eduardo Kerzberg,Ivan Castellví,François Spertini,Vivien M. Hsu,Thierry Martin,Tim Schmeiser,Dominik Majewski; Vera Bernardino,Piercarlo Sarzi Puttini

DOI: https://doi.org/10.1136/annrheumdis-2020-217455

IF: 27.973

2020-09-28

Annals of the Rheumatic Diseases

Abstract:Objectives To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials And Research (EUSTAR) database over long-term follow-up. Methods Eligible patients with SSc-ILD were registered in the EUSTAR database and had measurements of forced vital capacity (FVC) at baseline and after 12±3 months. Long-term progressive ILD and progression patterns were assessed in patients with multiple FVC measurements. Potential predictors of ILD progression were analysed using multivariable mixed-effect models. Results 826 patients with SSc-ILD were included. Over 12±3 months, 219 (27%) showed progressive ILD: either moderate (FVC decline 5% to 10%) or significant (FVC decline >10%). A total of 535 (65%) patients had multiple FVC measurements available over mean 5-year follow-up. In each 12-month period, 23% to 27% of SSc-ILD patients showed progressive ILD, but only a minority of patients showed progression in consecutive periods. Most patients with progressive ILD (58%) had a pattern of slow lung function decline, with more periods of stability/improvement than decline, whereas only 8% showed rapid, continuously declining FVC; 178 (33%) experienced no episode of FVC decline. The strongest predictive factors for FVC decline over 5 years were male sex, higher modified Rodnan skin score and reflux/dysphagia symptoms. Conclusion SSc-ILD shows a heterogeneous and variable disease course, and thus monitoring all patients closely is important. Novel treatment concepts, with treatment initiation before FVC decline occurs, should aim for prevention of progression to avoid irreversible organ damage.

rheumatology
Interstitial Lung Disease Associated with Systemic Sclerosis

Valentine Mismetti,Salim Si-Mohamed,Vincent Cottin

DOI: https://doi.org/10.1055/s-0044-1786698

2024-05-08

Seminars in Respiratory and Critical Care Medicine

Abstract:Systemic sclerosis (SSc) is a rare autoimmune disease characterized by a tripod combining vasculopathy, fibrosis, and immune-mediated inflammatory processes. The prevalence of interstitial lung disease (ILD) in SSc varies according to the methods used to detect it, ranging from 25 to 95%. The fibrotic and vascular pulmonary manifestations of SSc, particularly ILD, are the main causes of morbidity and mortality, contributing to 35% of deaths. Although early trials were conducted with cyclophosphamide, more recent randomized controlled trials have been performed to assess the efficacy and tolerability of several medications, mostly mycophenolate, rituximab, tocilizumab, and nintedanib. Although many uncertainties remain, expert consensus is emerging to optimize the therapeutic management and to provide clinicians with evidence-based clinical practice guidelines for patients with SSc-ILD. This article provides an overview, in the light of the latest advances, of the available evidence for the diagnosis and management of SSc-ILD. Article published online: 07 May 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

respiratory system,critical care medicine
Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort

Scheidegger,M.,Boubaya,M.,Garaiman,A.,Barua,I.,Becker,M.,Bjorkekjaer,H. J.,Bruni,C.,Dobrota,R.,Fretheim,H.,Jordan,S.,Midtvedt,O.,Mihai,C.,Hoffmann-Vold,A.-M.,Distler,O.,Elhai,M.

DOI: https://doi.org/10.1136/rmdopen-2023-003658

2024-01-11

RMD Open

Abstract:Background Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). According to expert statements, not all SSc-ILD patients require pharmacological therapy. Objectives To describe disease characteristics and disease course in untreated SSc-ILD patients in two well characterised SSc-ILD cohorts. Methods Patients were classified as treated if they had received a potential ILD-modifying drug. ILD progression in untreated patients was defined as (1) decline in forced vital capacity (FVC) from baseline of ≥10% or (2) decline in FVC of 5%–9% associated with a decline in diffusing capacity for carbon monoxide (DLCO)≥15% over 12±3 months or (3) start of any ILD-modifying treatment or (4) increase in the ILD extent during follow-up. Multivariable logistic regression was performed to identify factors associated with non-prescription of ILD-modifying treatment at baseline. Prognostic factors for progression in untreated patients were tested by multivariate Cox regression. Results Of 386 SSc-ILD included patients, 287 (74%) were untreated at baseline. Anticentromere antibodies (OR: 6.75 (2.16–21.14), p=0.001), limited extent of ILD (OR: 2.39 (1.19–4.82), p=0.015), longer disease duration (OR: 1.04 (1.00–1.08), p=0.038) and a higher DLCO (OR: 1.02 (1.01–1.04), p=0.005) were independently associated with no ILD-modifying treatment at baseline. Among 234 untreated patients, the 3 year cumulative incidence of progression was 39.9% (32.9–46.2). Diffuse cutaneous SSc and extensive lung fibrosis independently predicted ILD progression in untreated patients. Conclusion As about 40% of untreated patients show ILD progression after 3 years and effective and safe therapies for SSc-ILD are available, our results support a change in clinical practice in selecting patients for treatment.

rheumatology
Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: A systematic review from the Italian Society of Rheumatology

Gianluca Sambataro,Francesco Ferro,Martina Orlandi,Domenico Sambataro,Sebastiano Emanuele Torrisi,Luca Quartuccio,Carlo Vancheri,Chiara Baldini,Marco Matucci Cerinic

DOI: https://doi.org/10.1016/j.autrev.2019.102447

Abstract:Objective: To evaluate the prevalence, clinical presentation, serological and morphological features of, and therapeutic options for Interstitial Lung Disease (ILD) in primary Sjögren's Syndrome (pSS). Methods: Pubmed was searched between February 1996 and December 2018 using a combination of MESH terms related to pSS and ILD. Selected works were subjected to blind evaluation by two authors and a senior author in case of disagreement. The work followed PRISMA guidelines and was registered on PROSPERO (CRD42018118669). Results: About 20% of pSS patients have ILD, with a 5-y survival of 84% and a need for supplemental oxygen in the 11-33% range. A significant proportion of ILD patients are seronegative without sicca syndrome. ILD seems to be associated with higher levels of Lactic Dehydrogenases and positivity for Anti-Ro52k. The prevalent pattern in High Resolution Computed Tomography is Nonspecific Interstitial Pneumonia (NSIP), but all other patterns can be present. No difference in mortality was found between patients with NSIP and Usual Interstitial Pneumonia patterns. Amyloidosis and primary lung lymphoma can be observed in about 10% of pSS patients. Conclusion: The recognition of pSS underlying an ILD can be challenging in seronegative patients with no or mild sicca symptoms. A complete diagnostic assessment, including minor salivary glands and, in some cases, lung biopsy, should be performed on all patients at risk. A better recognition of the clinical or serological markers of ILD progression in these patients is warranted to drive the physicians to an early diagnosis and an effective treatment.
Influence of gastro-intestinal nematodes on the productivity of dairy cattle in the wet highlands of Sri Lanka

J. Rond,R. Jong,J. Boon,B. Brouwer

DOI: https://doi.org/10.1007/BF02239843

1990-05-01

Tropical Animal Health and Production

Abstract:
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease

Owen A. Moore,Nicole Goh,Tamera Corte,Hannah Rouse,Oliver Hennessy,Vivek Thakkar,Jillian Byron,Joanne Sahhar,Janet Roddy,Eli Gabbay,Peter Youssef,Peter Nash,Jane Zochling,Susanna M. Proudman,Wendy Stevens,Mandana Nikpour,O. A. Moore,N. Goh,T. Corte,H. Rouse,O. Hennessy,V. Thakkar,J. Byron,J. Sahhar,J. Roddy,E. Gabbay,P. Youssef,P. Nash,J. Zochling,S. M. Proudman,W. Stevens,M. Nikpour

DOI: https://doi.org/10.1093/rheumatology/kes289

2012-10-13

Rheumatology

Abstract:OBJECTIVES: In a multi-centre study, we sought to determine whether extent of disease on high-resolution CT (HRCT) lung, reported using a simple grading system, is predictive of decline and mortality in SSc-related interstitial lung disease (SSc-ILD), independently of pulmonary function tests (PFTs) and other prognostic variables.METHODS: SSc patients with a baseline HRCT performed at the time of ILD diagnosis were identified. All HRCTs and PFTs performed during follow-up were retrieved. Demographic and disease-related data were prospectively collected. HRCTs were graded according to the percentage of lung disease: >20%: extensive; <20%: limited; unclear: indeterminate. Indeterminate HRCTs were converted to limited or extensive using a forced vital capacity threshold of 70%. The composite outcome variable was deterioration (need for home oxygen or lung transplantation), or death.RESULTS: Among 172 patients followed for mean (s.d.) of 3.5 (2.9) years, there were 30 outcome events. In Weibull multivariable hazards regression modelling, baseline HRCT grade was independently predictive of outcome, with an adjusted hazard ratio (aHR) = 3.0, 95% CI 1.2, 7.5 and P = 0.02. In time-varying covariate models (based on 1309 serial PFTs and 353 serial HRCTs in 172 patients), serial diffusing capacity of the lung for carbon monoxide by alveolar volume ratio (ml/min/mmHg/l) (aHR = 0.4; 95% CI 0.3, 0.7; P = 0.001) and forced vital capacity (dl) (aHR = 0.9; 95% CI 0.8, 0.97; P = 0.008), were also strongly predictive of outcome.CONCLUSION: Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease. Serial PFTs are informative in follow-up of patients.

rheumatology
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

DOI: https://doi.org/10.1186/s12931-022-02292-3

IF: 5.8

2023-01-10

Respiratory Research

Abstract:Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and accounting for 20–40% of mortality. Evolution of therapeutic options has resulted in a lack of consensus on how to manage this condition. This Delphi study was initiated to develop consensus recommendations based on expert physician insights regarding screening, progression, treatment criteria, monitoring of response, and the role of recent therapeutic advances with antifibrotics and immunosuppressants in patients with SSc-ILD.

respiratory system
IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease

Antonio Giovanni Versace,Alessandra Bitto,Carmelo Ioppolo,Caterina Oriana Aragona,Daniela La Rosa,William Neal Roberts,Tommaso D'Angelo,Antonella Cinquegrani,Santa Cirmi,Natasha Irrera,Michele Navarra,Salvatore Corrao,Sebastiano Gangemi,Gianluca Bagnato

DOI: https://doi.org/10.3389/fmed.2022.825567

IF: 3.9

2022-02-17

Frontiers in Medicine

Abstract:Objective Systemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis. Our aim was to test whether both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared to SSc patients without ILD and healthy controls. Methods Serum levels of IL-13 and IL-33 were measured in 30 SSc patients with diffuse disease and 30 healthy controls by enzyme-linked immunosorbent assay. The extent of pulmonary fibrosis was assessed according to HRCT Warrick score. Pulmonary function tests included lung diffusion capacity for carbon monoxide, forced vital capacity and total lung capacity. Results Both IL-13 and IL-33 levels were increased in SSc patients compared to controls and significantly associated each other. DLco, FVC and TLC scores were inversely associated with IL-33 and IL-13 levels. Both IL-33 and IL-13 levels were significantly associated with the Warrick severity score and higher in the group of SSc patients with reduced pulmonary function compared to SSc patients with normal pulmonary function tests. Conclusion The IL-13/IL-33 axis needs to be further explored in longitudinal studies of SSc-ILD patients to assess its validity as a biomarker and future treatment target, as does downstream mediator ST2.

medicine, general & internal
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database

Gemma Lepri,Cosimo Bruni,Lorenzo Tofani,Alberto Moggi-Pignone,Martina Orlandi,Sara Tomassetti,Michael Hughes,Francesco Del Galdo,Rosaria Irace,Oliver Distler,Valeria Riccieri,Yannick Allanore,Ana Maria Gheorghiu,Elise Siegert,Jeska De Vries-Bouwstra,Eric Hachulla,Mohammed Tikly,Nemanja Damjanov,Francois Spertini,Luc Mouthon,Anna-Maria Hoffmann-Vold,Armando Gabrielli,Serena Guiducci,Marco Matucci-Cerinic,Daniel Furst,Silvia Bellando-Randone,EUSTAR Collaborators EUSTAR Collaborators

DOI: https://doi.org/10.3390/diagnostics14030295

IF: 3.6

2024-01-30

Diagnostics

Abstract:Background and Objectives: In SSc, ILD is a major cause of morbidity and mortality. We aimed to investigate the performance of DLCO (diffusing capacity of lung carbon monoxide) and FVC (forced vital capacity) delta change (Δ) and baseline values in predicting the development of SSc-ILD. Methods: Longitudinal data of DLCO, FVC, and ILD on the HRCT of SSc patients from the EUSTAR database were evaluated at baseline (t0) and after 12 (±4) (t1) and 24 (±4) (t2) months. Results: 474/17805 patients were eligible for the study (403 females); 46 (9.7%) developed ILD at t2. Positivity for anti-topoisomerase antibodies (117 patients) showed an association with ILD development at t2 (p = 0.0031). Neither the mean t0 to t1 change (Δ) of DLCO nor the mean t0 to t1 FVCΔ predicted the appearance of ILD at t2. Investigating the possible role of baseline DLCO and FVC values in predicting ILD appearance after 24 (±4) months, we observed a moderate predictive capability of t0 DLCO < 80%, stronger than that of FVC < 80%. Conclusions: We suggest that an impaired baseline DLCO may be predictive of the appearance of ILD after 2 years of follow-up. This result advances the hypothesis that a reduction in gas exchange may be considered an early sign of lung involvement. However, further rigorous studies are warranted to understand the predictive role of DLCO evaluation in the course of SSc.

medicine, general & internal
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact

Martina Bonifazi,Nicola Sverzellati,Eva Negri,Joseph Jacob,Ryoko Egashira,Joanna Moser,Sara Piciucchi,Federico Mei,Angelo De Lauretis,Dina Visca,Nicole Goh,Matteo Bonini,Laura Cirilli,Carlo La Vecchia,Felix Chua,Vasileios Kouranos,George Margaritopoulos,Maria Kokosi,Toby M. Maher,Stefano Gasparini,Armando Gabrielli,Athol U. Wells,Elisabetta A. Renzoni

DOI: https://doi.org/10.1183/13993003.02135-2019

IF: 24.3

2020-04-16

European Respiratory Journal

Abstract:Interstitial lung disease (ILD) in systemic sclerosis (SSc) is a major cause of morbidity and mortality, mostly presenting as non-specific interstitial pneumonia. Little is known about the prevalence of pleuroparenchymal fibroelastosis (PPFE), a specific entity affecting the visceral pleura and subpleural parenchyma. We set out to estimate PPFE prevalence in two large cohorts of SSc patients and to assess its impact on survival and functional decline. A total of 359 SSc patients, derived from two referral centres in two different countries (UK and Italy), were included. The first available high-resolution computed tomography scan was independently evaluated by two radiologists blind to clinical information, to quantify ILD extent, freestanding bronchial abnormalities, and lobar percentage involvement of PPFE on a four-point categorical scale. Discordant scores were adjudicated by a third scorer. PPFE extent was further classified as limited (≤2/18) or extensive (>2/18). Results were evaluated against functional decline and mortality. The overall prevalence of PPFE in the combined SSc population was 18% (11% with extensive PPFE), with no substantial difference between the two cohorts. PPFE was significantly linked to free-standing bronchial abnormalities (61% versus 25% in PPFE versus no PPFE; p<0.0001) and to worse survival, independently of ILD severity or short-term lung function changes (HR 1.89, 95% CI 1.10–3.25; p=0.005). In the current study, we provide an exhaustive description of PPFE prevalence and clinical impact in the largest cohort of SSc subjects published so far. PPFE presence should be carefully considered, due to its significant prognostic implications.

respiratory system
Characterisation of incident interstitial lung disease in late systemic sclerosis

Sabrina Hoa,Claudie Berger,Nouha Lahmek,Maggie Larche,Mohammed Osman,May Choi,Janet Pope,Carter Thorne,Canadian Scleroderma Research Group,Marie Hudson

DOI: https://doi.org/10.1002/art.43051

2024-11-05

Arthritis & Rheumatology

Abstract:Objective Interstitial lung disease (ILD) is a common and potentially lethal complication of systemic sclerosis (SSc). Screening by HRCT is recommended in all patients with risk factors, including early disease. Little is known on late presentations of ILD. This study aimed to characterize the incidence, risk factors and outcomes of late‐onset SSc‐ILD. Methods Subjects enrolled in the Canadian Scleroderma Research Group (CSRG) cohort from 2004 to 2020 without prevalent ILD were included. Incidence and risk factors for ILD (on HRCT) were compared according to disease duration above (late) and below (earlier) 7 years from first non‐Raynaud manifestation. Risk of ILD progression was compared using Kaplan‐Meier and multivariable Cox models. Results Overall, 199/969 (21%) patients developed incident ILD over a median of 2.4 [1.2, 4.3] years. The incidence rate in late SSc (3.7/100 person‐years) was lower than in earlier SSc (relative risk 0.68, 95%CI:0.51‐0.92). Risk factors for incident ILD included male sex, diffuse subtype, myositis, anti‐topoisomerase I autoantibodies and higher C‐reactive protein levels. Patients with late‐onset ILD were also less frequently White and more frequently had arthritis and anti‐RNA‐polymerase III autoantibodies. Lung disease severity was similar between late‐ and earlier‐onset SSc‐ILD (FVC 88% and 87%, DLCO 64% and 62%, respectively). Progression rates were also similar between late‐ and earlier‐onset SSc‐ILD (log‐rank p=0.8, hazard ratio 1.11, 95% CI: 0.58‐2.10). Conclusion ILD can present in late SSc. Risk factors and progression rates overlapped with earlier‐onset SSc‐ILD. Surveillance for ILD should continue in longstanding SSc. Frequency and modality of monitoring remain to be defined.

rheumatology
The Treatment of Lung Involvement in Systemic Sclerosis

Barbara Ruaro,Marco Confalonieri,Marco Matucci-Cerinic,Francesco Salton,Paola Confalonieri,Mario Santagiuliana,Gloria Maria Citton,Elisa Baratella,Cosimo Bruni

DOI: https://doi.org/10.3390/ph14020154

IF: 4.6

2021-02-13

Pharmaceuticals

Abstract:Systemic sclerosis (SSc) patients are often affected by interstitial lung disease (ILD) and, although there have been recent treatment advances, it remains the leading cause of death among SSc, with a 10-year mortality up to 40%. African Americans and subjects with diffuse cutaneous SSc or anti-topoisomerase 1 antibodies are most commonly affected. Currently, early ILD diagnosis can be made, and it is pivotal to improve the prognosis. The diagnostic mainstay test for SSc-ILD is high-resolution computed tomography for the morphology and pulmonary function tests for the functional aspects. Treatment planning and intensity are guided by the disease severity and risk of progression. Traditionally, therapy has depended on combinations of immunosuppressants, particularly cyclophosphamide and mycophenolate mofetil, which can be supplemented by targeted biological and antifibrotic therapies. Benefits have been observed in trials on hematopoietic autologous stem cell transplantation for patients with progressive SSc, whilst lung transplantation is reserved for refractory SSc-ILD cases. Herein, recent advances in SSc-ILD treatment will be explored.

pharmacology & pharmacy,chemistry, medicinal
Lung involvement in systemic sclerosis

Corrado Campochiaro,Cosimo Bruni,Sara Tomassetti,Lorenzo Dagna,Marco Matucci-Cerinic

DOI: https://doi.org/10.1016/b978-0-323-91083-5.00009-8

2022-01-01

Handbook of Systemic Autoimmune Diseases

Abstract:Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, immune system activation, and fibrosis of the skin and internal organs [1]. While over the recent years, the prognosis of SSc patients has greatly improved, thanks to a better understanding of the underlying pathogenetic phenomena and the arousal of targeted therapies, the disease still presents the highest morbidity and mortality among all connective tissue diseases [2]. Compared to those years when SSc renal crisis represented the leading cause of death, now in the last decades, lung involvement (both pulmonary hypertension and pulmonary fibrosis) has become the primary cause of SSc-related death [3]. Therefore, clinicians involved in SSc care should be aware of the most recent evolutions in the field of SSc with particular attention to lung involvement. In fact, the early detection and the prompt treatment both of fibrotic and vascular lung disease may have fundamental impact on patients' quality of life and survival. In SSc, lung involvement is characterized by interstitial lung disease (ILD), which is due to the fibrosis of the alveolo-capillary membrane, and pulmonary arterial hypertension (PAH), which reflects the proliferative vasculopathy affecting pulmonary vessels [1,4,5]. Usually, SSc is classified according to 2013 ACR/EULAR criteria [6] and is also subsetted in a limited cutaneous (lcSSc; affecting the face, neck and distal limbs) and a diffuse cutaneous SSc (dcSSc; affecting the proximal limbs, abdomen, and chest). Both subsets are associated with specific clinical features and autoantibody positivity [7]. In this chapter, either SSc-ILD or SSc-PAH will be discussed, and, given the historical period, the clinical and prognostic data on COVID-19 in SSc patients will be also presented.

English Else
Tectus (Trochus) niloticus search for suitable habitats can cause equivocal benefits of protection in village-based marine reserves

P. Dumas,J. Ham,R. Kaku,A. William,J. Kaltavara,S. Gereva,M. Léopold

DOI: https://doi.org/10.1371/journal.pone.0176922

IF: 3.7

2017-05-02

PLoS ONE

Abstract:In the Pacific, the protection of coral reef resources is often achieved through the implementation of village-based marine reserves (VBMRs). While substantial fisheries benefits are often reported, results of quantitative approaches are controversial for benthic macroinvertebrates, whose life history traits may cause low congruence with protective measures implemented at non-ecologically relevant scales. This study investigated the structural and behavioral responses of the exploited topshell Tectus niloticus within a very small (0.2 km2) VBMR in Vanuatu, south Pacific. The results of underwater surveys and a nine-month tagging experiment emphasized contrasted, scale-dependent responses. At the reserve scale, our results failed to demonstrate any positive effect of protection after three years of closure. In contrast, abundance, density and biomass increased more than ten-fold in the southern part of the reserve, along with significantly larger (25%) individual sizes. The dispersal of tagged specimens was also consistently lower after 2, 4 and 9 months in the latter zone. Analyses of 17 substratum variables revealed a marked small-scale patchiness delineating contrasted benthic microhabitats, the distribution of which closely matched that of trochus. We advocate that i) VBMRs have inherently unequal ecological potentials for protecting and managing highly habitat-dependent species such as trochus; ii) ‘success’ or ‘failure’ is to a certain extent pre-determined by the trajectory of species-specific microhabitats, which may outreach protection effects. This has strong implications in the Pacific where the location and size of reserves primarily depends upon marine tenure, and communities have little flexibility in setting reserve boundaries.
Lung vascular changes as biomarkers of severity in systemic sclerosis-associated interstitial lung disease

Cosimo Bruni,Mariaelena Occhipinti,Michael Pienn,Gianna Camiciottoli,Maurizio Bartolucci,Silvia Laura Bosello,Christian Payer,Zoltán Bálint,Anna Rita Larici,Alessandra Tottoli,Lorenzo Tofani,Enrico De Lorenzis,Gemma Lepri,Silvia Bellando-Randone,Amelia Spinella,Dilia Giuggioli,Francesco Masini,Giovanna Cuomo,Federico Lavorini,Stefano Colagrande,Horst Olschewski,Marco Matucci-Cerinic

DOI: https://doi.org/10.1093/rheumatology/keac311

2023-02-01

Abstract:Objectives: It has recently become possible to assess lung vascular and parenchymal changes quantitatively in thoracic CT images using automated software tools. We investigated the vessel parameters of patients with SSc, quantified by CT imaging, and correlated them with interstitial lung disease (ILD) features. Methods: SSc patients undergoing standard of care pulmonary function testing and CT evaluation were retrospectively evaluated. CT images were analysed for ILD patterns and total pulmonary vascular volume (PVV) extents with Imbio lung texture analysis. Vascular analysis (volumes, numbers and densities of vessels, separating arteries and veins) was performed with an in-house developed software. A threshold of 5% ILD extent was chosen to define the presence of ILD, and commonly used cut-offs of lung function were adopted. Results: A total of 79 patients [52 women, 40 ILD, mean age 56.2 (s.d. 14.2) years, total ILD extent 9.5 (10.7)%, PVV/lung volume % 2.8%] were enrolled. Vascular parameters for total and separated PVV significantly correlated with functional parameters and ILD pattern extents. SSc-associated ILD (SSc-ILD) patients presented with an increased number and volume of arterial vessels, in particular those between 2 and 4 mm of diameter, and with a higher density of arteries and veins of <6 mm in diameter. Considering radiological and functional criteria concomitantly, as well as the descriptive trends from the longitudinal evaluations, the normalized PVVs, vessel numbers and densities increased progressively with the increase/worsening of ILD extent and functional impairment. Conclusion: In SSc patients CT vessel parameters increase in parallel with ILD extent and functional impairment, and may represent a biomarker of SSc-ILD severity.
Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

Patricia Richter,Anca Cardoneanu,Nicoleta Dima,Ioana Bratoiu,Ciprian Rezus,Alexandra Maria Burlui,Damiana Costin,Luana Andreea Macovei,Elena Rezus

DOI: https://doi.org/10.3390/ijms24119388

IF: 5.6

2023-05-28

International Journal of Molecular Sciences

Abstract:Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.

biochemistry & molecular biology,chemistry, multidisciplinary
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis

Pia Moinzadeh,Francesco Bonella,Max Oberste,Jithmi Weliwitage,Nobert Blank,Gabriela Riemekasten,Ulf Müller-Ladner,Jörg Henes,Elise Siegert,Claudia Günther,Ina Kötter,Christiane Pfeiffer,Marc Schmalzing,Gabriele Zeidler,Peter Korsten,Laura Susok,Aaron Juche,Margitta Worm,Ilona Jandova,Jan Ehrchen,Cord Sunderkötter,Gernot Keyßer,Andreas Ramming,Tim Schmeiser,Alexander Kreuter,Hanns-Martin Lorenz,Nicolas Hunzelmann,Michael Kreuter

DOI: https://doi.org/10.1016/j.chest.2023.08.013

IF: 9.6

Chest

Abstract:Background: Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD-PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis. Research question: Does SSc-associated ILD-PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact? Study design and methods: Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry. Kaplan-Meier estimates were used to compare overall survival in patients with SSc-associated ILD-PH and ILD without PH with patients without pulmonary involvement and those with PAH. The Cox proportional hazard model was used to analyze the influence of pulmonary involvement and other potential predictors on patient survival. Results: Clinical data of 3,257 patients with a mean follow-up time of 3.45 ± 1.63 years have been included in our analysis. At baseline, ILD was present in 34.5%, whereas PH without ILD had a lower prevalence with 4.5%. At the end of follow-up, 47.6% of patients with SSc had ILD, 15.2% had ILD-PH, and 6.5% had PAH. ILD was more frequent in the diffuse cutaneous form (57.3%), whereas PAH did not differ significantly between SSc subtypes. Significant differences in baseline characteristics between PAH vs ILD-PH vs ILD without PH were found for age at diagnosis, sex, SSc subsets, antibody status, FVC, diffusing capacity of the lung for carbon monoxide, and therapy. Overall survival at 5 years was 96.4% for patients without pulmonary involvement and differed significantly between patients with ILD without PH, PAH, and being worst in patients with ILD-PH. Female sex (hazard ratio [HR], 0.3), higher BMI (HR, 0.9), and higher diffusing capacity of the lung for carbon monoxide values (HR, 0.98) were associated with a lower mortality risk. Interpretation: ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.
Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis

Surabhi Agarwal Khanna,John W. Nance,Sally A. Suliman

DOI: https://doi.org/10.1007/s11926-022-01067-5

2022-05-04

Current Rheumatology Reports

Abstract:Purpose of Review Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc). We explore the importance of early detection, monitoring, and management of SSc-ILD. Recent Findings All patients with SSc are at risk of ILD and should be screened for ILD at diagnosis using a high-resolution computed tomography (HRCT) scan. Some patients with SSc-ILD develop a progressive phenotype characterized by worsening fibrosis on HRCT, decline in lung function, and early mortality. To evaluate progression and inform treatment decisions, regular monitoring is important and should include pulmonary function testing, evaluation of symptoms and quality of life, and, where indicated, repeat HRCT. Multidisciplinary discussion enables comprehensive evaluation of the available information and its implications for management. The first-line treatment for SSc-ILD is usually immunosuppression. The antifibrotic drug nintedanib has been approved for slowing lung function decline in patients with SSc-ILD. Summary Optimal management of patients with SSc-ILD requires a multidisciplinary and patient-centered approach.

rheumatology

[Long-term theophylline therapy of bronchial asthma].

Predictors of progression in systemic sclerosis patients with interstitial lung disease

The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Interstitial Lung Disease Associated with Systemic Sclerosis

Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort

Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: A systematic review from the Italian Society of Rheumatology

Influence of gastro-intestinal nematodes on the productivity of dairy cattle in the wet highlands of Sri Lanka

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease

The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database

Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact

Characterisation of incident interstitial lung disease in late systemic sclerosis

The Treatment of Lung Involvement in Systemic Sclerosis

Lung involvement in systemic sclerosis

Tectus (Trochus) niloticus search for suitable habitats can cause equivocal benefits of protection in village-based marine reserves

Lung vascular changes as biomarkers of severity in systemic sclerosis-associated interstitial lung disease

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis

Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis